ASX - By Stock
|
RCE |
Re:
Ann: Appendix 4D and Interim Financial Report
|
|
Rusty0286
|
1 |
1.3K |
0 |
09/03/22 |
09/03/22 |
ASX - By Stock
|
1
|
1.3K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Safety Continues in 3rd Cohort PhI Clinical Trial
|
|
Rusty0286
|
56 |
19K |
0 |
01/03/22 |
01/03/22 |
ASX - By Stock
|
56
|
19K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Safety Continues in 3rd Cohort PhI Clinical Trial
|
|
Rusty0286
|
56 |
19K |
0 |
01/03/22 |
01/03/22 |
ASX - By Stock
|
56
|
19K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Safety Continues in 3rd Cohort PhI Clinical Trial
|
|
Rusty0286
|
56 |
19K |
1 |
01/03/22 |
01/03/22 |
ASX - By Stock
|
56
|
19K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Safety Continues in 3rd Cohort PhI Clinical Trial
|
|
Rusty0286
|
56 |
19K |
0 |
28/02/22 |
28/02/22 |
ASX - By Stock
|
56
|
19K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Safety Continues in 3rd Cohort PhI Clinical Trial
|
|
Rusty0286
|
56 |
19K |
1 |
28/02/22 |
28/02/22 |
ASX - By Stock
|
56
|
19K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Safety Continues in 3rd Cohort PhI Clinical Trial
|
|
Rusty0286
|
56 |
19K |
0 |
28/02/22 |
28/02/22 |
ASX - By Stock
|
56
|
19K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Safety Continues in 3rd Cohort PhI Clinical Trial
|
|
Rusty0286
|
56 |
19K |
1 |
28/02/22 |
28/02/22 |
ASX - By Stock
|
56
|
19K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Safety Continues in 3rd Cohort PhI Clinical Trial
|
|
Rusty0286
|
56 |
19K |
0 |
26/02/22 |
26/02/22 |
ASX - By Stock
|
56
|
19K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Safety Continues in 3rd Cohort PhI Clinical Trial
|
|
Rusty0286
|
56 |
19K |
0 |
25/02/22 |
25/02/22 |
ASX - By Stock
|
56
|
19K
|
0
|
|
ASX - By Stock
|
RCE Biotech |
Re:
RCE Charts
|
|
Rusty0286
|
2.1K |
642K |
0 |
20/01/22 |
20/01/22 |
ASX - By Stock
|
2.1K
|
642K
|
0
|
|
ASX - By Stock
|
RCE Biotech |
Re:
RCE Charts
|
|
Rusty0286
|
2.1K |
642K |
6 |
29/04/21 |
29/04/21 |
ASX - By Stock
|
2.1K
|
642K
|
6
|
|
ASX - By Stock
|
RCE Biotech |
Re:
RCE Charts
|
|
Rusty0286
|
2.1K |
642K |
0 |
27/04/21 |
27/04/21 |
ASX - By Stock
|
2.1K
|
642K
|
0
|
|
ASX - By Stock
|
RCE Biotech |
Re:
RCE Charts
|
|
Rusty0286
|
2.1K |
642K |
0 |
27/04/21 |
27/04/21 |
ASX - By Stock
|
2.1K
|
642K
|
0
|
|
ASX - By Stock
|
RCE Biotech |
Re:
RCE Charts
|
|
Rusty0286
|
2.1K |
642K |
2 |
27/04/21 |
27/04/21 |
ASX - By Stock
|
2.1K
|
642K
|
2
|
|
ASX - By Stock
|
RCE Biotech |
Re:
RCE Charts
|
|
Rusty0286
|
2.1K |
642K |
1 |
23/04/21 |
23/04/21 |
ASX - By Stock
|
2.1K
|
642K
|
1
|
|
ASX - By Stock
|
RCE Biotech |
Re:
RCE Charts
|
|
Rusty0286
|
2.1K |
642K |
0 |
23/04/21 |
23/04/21 |
ASX - By Stock
|
2.1K
|
642K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
RCE Evaluation
|
|
Rusty0286
|
22 |
7.5K |
0 |
16/04/21 |
16/04/21 |
ASX - By Stock
|
22
|
7.5K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
Ann: RECCE 327 Registered for Topical Burns Study in Humans
|
|
Rusty0286
|
33 |
6.7K |
0 |
15/04/21 |
15/04/21 |
ASX - By Stock
|
33
|
6.7K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
RCE Evaluation
|
|
Rusty0286
|
22 |
7.5K |
1 |
13/04/21 |
13/04/21 |
ASX - By Stock
|
22
|
7.5K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
RCE Evaluation
|
|
Rusty0286
|
22 |
7.5K |
1 |
13/04/21 |
13/04/21 |
ASX - By Stock
|
22
|
7.5K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
RCE Evaluation
|
|
Rusty0286
|
22 |
7.5K |
2 |
13/04/21 |
13/04/21 |
ASX - By Stock
|
22
|
7.5K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
RCE Evaluation
|
|
Rusty0286
|
22 |
7.5K |
1 |
13/04/21 |
13/04/21 |
ASX - By Stock
|
22
|
7.5K
|
1
|
|
ASX - By Stock
|
RCE |
RCE Evaluation
|
|
Rusty0286
|
22 |
7.5K |
3 |
12/04/21 |
12/04/21 |
ASX - By Stock
|
22
|
7.5K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
RCE Media
|
|
Rusty0286
|
370 |
108K |
0 |
16/11/20 |
16/11/20 |
ASX - By Stock
|
370
|
108K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
RCE Media
|
|
Rusty0286
|
370 |
108K |
0 |
11/11/20 |
11/11/20 |
ASX - By Stock
|
370
|
108K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
RCE Media
|
|
Rusty0286
|
370 |
108K |
1 |
11/11/20 |
11/11/20 |
ASX - By Stock
|
370
|
108K
|
1
|
|